RARE
Ultragenyx Pharmaceutical Inc. Health Care Pharmaceutical Preparations Russell 3000
$16.10Close
$1.6BMarket cap
$12.88 – $36.5452-week range
Nov 3, 2026Next report · after the close
Highlights
Cautions
- Not in an uptrend 1 of 8 trend conditions
- Lagging the market RS 5 · weaker than 95% of stocks over 12 months
- Far from its high 56% below its 52-week high
- Results soon Nov 3, 2026, in 2 days
- Financial distress Altman Z″ in the distress zone
Price
Filing Results Screen pick 52-week high and low Adjusted prices
Key figures
Off 12-month high
56%
1wk
up 2.9%
price change
1mo
up 7.1%
price change
12-month return
down 54%
market up 11% ·
its own down 64%
F-score
—
— Not assessed
Altman Z
-3.83
Elevated risk
P/E
—
price / earnings
PEG
—
P/E / EPS growth
P/B
—
price / book
Earnings yield
down 47.2%
EBIT / enterprise value
Cheaper than
2%
of the market · expensive
Revenue growth
up 20%
year on year
EPS growth
—
latest quarter
Sales growth
up 28%
latest quarter · +30 pts
ROE
—
return on equity
Free cash margin
down 70%
-$472.0M FCF
D/E
—
long-term debt / equity
Net debt / EBITDA
—
Interest cover
—EBIT / interest
Trade setup
ATR%
5.3%
$0.85 a day · 2×ATR $14.39
RS
5 / 99
vs the universe
Trend
1 / 8
trend template
Relative volume
0.5×
vs 50-day average
Up/down volume
0.92
50 sessions
Implied move
—
no option chain · report Nov 3, 2026
Trend template · 1 of 8
- 150-day average above the 200-day: passes
Screen verdict
Did not qualify for any screen.
Warning signs
- Liabilities exceed assets Shareholders' equity is negative at -$80.0M as of Dec 31, 2025. What is left for shareholders after creditors is, on the balance sheet, less than nothing.
- Bankruptcy model reads distressed The Altman score sits inside the range historically associated with financial distress. It is used here only to exclude, never to rank, and it is a statistical band rather than a prediction about this company.
- Shareholders diluted The share count rose 4.4% over the year, from 92m to 97m shares. Each existing share owns a smaller fraction of the company than it did a year ago.
Last reported
Aug 4, 2026
Last shock
Sep 3, 2026-44% in one session8.9× volumeon an SEC filing+8% since
Financials
- Net -85%
- Free cash -70%
- Cash
- Long-term debt
| FY2020Dec 31, 2020 | FY2021Dec 31, 2021 | FY2022Dec 31, 2022 | FY2023Dec 31, 2023 | FY2024Dec 31, 2024 | FY2025Dec 31, 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $271.0M | $351.4M | $363.3M | $434.0M | $560.0M | $673.0M |
| Operating income | -$330.1M | -$381.7M | -$648.9M | -$569.0M | -$536.0M | -$535.0M |
| Net income | -$186.6M | -$454.0M | -$707.4M | -$607.0M | -$569.0M | -$575.0M |
| Net margin | -69% | -129% | -195% | -140% | -102% | -85% |
| Earnings per share | -$3.07 | -$6.70 | -$10.12 | -$8.26 | -$6.29 | -$5.83 |
| Free cash flow | -$176.1M | -$411.8M | -$496.6M | -$519.0M | -$421.0M | -$472.0M |
| Free cash margin | -65% | -117% | -137% | -120% | -75% | -70% |
| Cash | $713.5M | $307.6M | $132.9M | $214.0M | $174.0M | $421.0M |
| Shareholders' equity | $1.2B | $922.6M | $352.0M | $275.0M | $255.0M | -$80.0M |
| Shares outstanding | 66.82m | 69.34m | 70.20m | 82.32m | 92.50m | 96.60m |
Filings
| Filed | Report | Period to | Lag |
|---|---|---|---|
| Aug 5, 2026 | Quarterly ↗ | Jun 30, 2026 | 36d |
| May 6, 2026 | Quarterly ↗ | Mar 31, 2026 | 36d |
| Feb 18, 2026 | Annual ↗ | Dec 31, 2025 | 49d |
| Nov 5, 2025 | Quarterly ↗ | Sep 30, 2025 | 36d |
| Aug 6, 2025 | Quarterly ↗ | Jun 30, 2025 | 37d |
| May 7, 2025 | Quarterly ↗ | Mar 31, 2025 | 37d |
| Feb 19, 2025 | Annual ↗ | Dec 31, 2024 | 50d |
| Nov 6, 2024 | Quarterly ↗ | Sep 30, 2024 | 37d |
| Aug 2, 2024 | Quarterly ↗ | Jun 30, 2024 | 33d |
| May 3, 2024 | Quarterly ↗ | Mar 31, 2024 | 33d |
| Feb 21, 2024 | Annual ↗ | Dec 31, 2023 | 52d |
| Nov 3, 2023 | Quarterly ↗ | Sep 30, 2023 | 34d |
Current reports
| Filed | Disclosed |
|---|---|
| Oct 19, 2026 | Other events ↗ |
| Oct 14, 2026 | Material agreement ↗ |
| Oct 7, 2026 | Material agreement ↗ |
| Sep 17, 2026 | Other events ↗ |
| Sep 2, 2026 | Other events ↗ |
| Aug 19, 2026 | Other events ↗ |
| Aug 11, 2026 | Other events ↗ |
| Aug 4, 2026 | Results ↗ |
| May 18, 2026 | Director or officer change · Shareholder vote ↗ |
| May 5, 2026 | Results ↗ |
| Apr 2, 2026 | Other events ↗ |
| Mar 30, 2026 | Other events ↗ |